EA008881B1 - Новые кристаллические формы {2-[1-(3,5-бис-трифторметилбензил)-5-пиридин-4-ил-1h-[1,2,3]триазол-4-ил]пиридин-3-ил}-(2-хлорфенил)метанона - Google Patents

Новые кристаллические формы {2-[1-(3,5-бис-трифторметилбензил)-5-пиридин-4-ил-1h-[1,2,3]триазол-4-ил]пиридин-3-ил}-(2-хлорфенил)метанона Download PDF

Info

Publication number
EA008881B1
EA008881B1 EA200600829A EA200600829A EA008881B1 EA 008881 B1 EA008881 B1 EA 008881B1 EA 200600829 A EA200600829 A EA 200600829A EA 200600829 A EA200600829 A EA 200600829A EA 008881 B1 EA008881 B1 EA 008881B1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyridin
methanone
chlorophenyl
triazol
peaks
Prior art date
Application number
EA200600829A
Other languages
English (en)
Russian (ru)
Other versions
EA200600829A1 (ru
Inventor
Карстен Тимпе
Альфио Боргезе
Дэвид Скотт Коффи
Пэмела Кайе Футман
Стивен Уэйн Педерсен
Сьюзан Мари Реутцель-Эденс
Шелла Ленйонга Тамезе
Карстен Вебер
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200600829A1 publication Critical patent/EA200600829A1/ru
Publication of EA008881B1 publication Critical patent/EA008881B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
EA200600829A 2003-10-24 2004-10-12 Новые кристаллические формы {2-[1-(3,5-бис-трифторметилбензил)-5-пиридин-4-ил-1h-[1,2,3]триазол-4-ил]пиридин-3-ил}-(2-хлорфенил)метанона EA008881B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51430003P 2003-10-24 2003-10-24
PCT/US2004/030914 WO2005042515A1 (en) 2003-10-24 2004-10-12 Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone

Publications (2)

Publication Number Publication Date
EA200600829A1 EA200600829A1 (ru) 2006-08-25
EA008881B1 true EA008881B1 (ru) 2007-08-31

Family

ID=34549327

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200600829A EA008881B1 (ru) 2003-10-24 2004-10-12 Новые кристаллические формы {2-[1-(3,5-бис-трифторметилбензил)-5-пиридин-4-ил-1h-[1,2,3]триазол-4-ил]пиридин-3-ил}-(2-хлорфенил)метанона

Country Status (28)

Country Link
US (1) US7381826B2 (cg-RX-API-DMAC7.html)
JP (1) JP4959336B2 (cg-RX-API-DMAC7.html)
KR (1) KR100848407B1 (cg-RX-API-DMAC7.html)
CN (1) CN1863791B (cg-RX-API-DMAC7.html)
AR (1) AR046131A1 (cg-RX-API-DMAC7.html)
AT (1) ATE462700T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004285855B8 (cg-RX-API-DMAC7.html)
BR (1) BRPI0415010B8 (cg-RX-API-DMAC7.html)
CA (1) CA2542140C (cg-RX-API-DMAC7.html)
CL (2) CL2009001311A1 (cg-RX-API-DMAC7.html)
CR (1) CR8353A (cg-RX-API-DMAC7.html)
DE (1) DE602004026333D1 (cg-RX-API-DMAC7.html)
DK (1) DK1675846T3 (cg-RX-API-DMAC7.html)
EA (1) EA008881B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP066517A (cg-RX-API-DMAC7.html)
ES (1) ES2340772T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20100207T1 (cg-RX-API-DMAC7.html)
IL (1) IL174926A0 (cg-RX-API-DMAC7.html)
MA (1) MA28329A1 (cg-RX-API-DMAC7.html)
MY (1) MY157375A (cg-RX-API-DMAC7.html)
NO (1) NO335090B1 (cg-RX-API-DMAC7.html)
NZ (2) NZ545917A (cg-RX-API-DMAC7.html)
PE (1) PE20050481A1 (cg-RX-API-DMAC7.html)
PT (1) PT1675846E (cg-RX-API-DMAC7.html)
TW (1) TW200524906A (cg-RX-API-DMAC7.html)
UA (1) UA82901C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005042515A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200603234B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2801220C2 (ru) * 2013-10-08 2023-08-03 Мейдзи Сейка Фарма Ко., Лтд. Кристаллические формы производного диазабициклооктана и способ их получения

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2121610B1 (en) * 2006-12-20 2014-04-02 Eli Lilly & Company Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
WO2009075778A2 (en) * 2007-12-06 2009-06-18 The Regents Of The University Of California Nonpeptidic inhibitors of cruzain
US8080568B1 (en) * 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
RU2770050C2 (ru) 2015-03-04 2022-04-14 Ванда Фармасьютиклз Инк. Способ лечения с применением традипитанта
WO2017031215A1 (en) * 2015-08-17 2017-02-23 Eli Lilly And Company Process development of a pyridine-containing nk-1 receptor antagonist
CA3073998A1 (en) 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
DK3710000T3 (da) * 2017-11-17 2025-06-16 Vanda Pharmaceuticals Inc Tradipitant til anvendelse til behandling af gastroparese
CN112218636B (zh) * 2018-06-08 2025-05-06 万达制药公司 使用川地匹坦进行治疗的方法
IL281569B2 (en) 2018-09-28 2025-04-01 Vanda Pharmaceuticals Inc Use of tradipient in motion sickness
US20220096449A1 (en) 2018-12-03 2022-03-31 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
KR20220145844A (ko) 2020-02-25 2022-10-31 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피탄트를 이용한 아토피 피부염의 개선된 치료
WO2021195205A1 (en) 2020-03-26 2021-09-30 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
AU2023413130A1 (en) 2022-12-21 2025-06-05 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant
EP4599831A1 (en) 2024-02-09 2025-08-13 Vanda Pharmaceuticals Inc. Treatment of gastroparesis with tradipitant
WO2026152024A1 (en) 2025-01-09 2026-07-16 Vanda Pharmaceuticals Inc. Method of treating nausea and vomiting after glp-1r agonist administration

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432952B1 (en) * 1999-10-29 2002-08-13 Merck & Co., Inc. Polymorphic form of a tachykinin receptor antagonist
WO2003091226A1 (en) * 2002-04-26 2003-11-06 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099067A1 (en) 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
GB9505492D0 (en) * 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
AU726745B2 (en) * 1996-10-07 2000-11-16 Merck Sharp & Dohme Limited CNS-penetrant NK-1 receptor antagonists as antidepressant and/or an anti-anxiety agent
DE60039616D1 (de) * 1999-08-13 2008-09-04 Vertex Pharma INHIBITOREN DER c-JUN N-TERMINALEN KINASE (JNK) UND ANDERE PROTEIN-KINASEN
US20020044971A1 (en) 2000-07-07 2002-04-18 Amidon Gordon L. Dissolution rate of poorly soluble drugs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432952B1 (en) * 1999-10-29 2002-08-13 Merck & Co., Inc. Polymorphic form of a tachykinin receptor antagonist
WO2003091226A1 (en) * 2002-04-26 2003-11-06 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2801220C2 (ru) * 2013-10-08 2023-08-03 Мейдзи Сейка Фарма Ко., Лтд. Кристаллические формы производного диазабициклооктана и способ их получения

Also Published As

Publication number Publication date
NZ580480A (en) 2010-02-26
CA2542140A1 (en) 2005-05-12
KR100848407B1 (ko) 2008-07-28
AR046131A1 (es) 2005-11-23
DE602004026333D1 (de) 2010-05-12
PT1675846E (pt) 2010-04-20
US20070078166A1 (en) 2007-04-05
CL2009001310A1 (es) 2009-12-04
CN1863791B (zh) 2011-12-07
DK1675846T3 (da) 2010-05-31
NZ545917A (en) 2009-11-27
BRPI0415010B8 (pt) 2021-05-25
AU2004285855A1 (en) 2005-05-12
NO20062371L (no) 2006-05-24
EA200600829A1 (ru) 2006-08-25
AU2004285855B8 (en) 2011-04-28
NO335090B1 (no) 2014-09-08
JP4959336B2 (ja) 2012-06-20
CL2009001311A1 (es) 2009-10-02
TW200524906A (en) 2005-08-01
ZA200603234B (en) 2007-07-25
IL174926A0 (en) 2006-08-20
BRPI0415010B1 (pt) 2019-07-09
WO2005042515A1 (en) 2005-05-12
PE20050481A1 (es) 2005-09-20
ATE462700T1 (de) 2010-04-15
US7381826B2 (en) 2008-06-03
HRP20100207T1 (hr) 2010-05-31
CN1863791A (zh) 2006-11-15
ES2340772T3 (es) 2010-06-09
JP2007509143A (ja) 2007-04-12
ECSP066517A (es) 2006-10-10
BRPI0415010A8 (pt) 2018-05-08
CR8353A (es) 2006-06-06
MA28329A1 (fr) 2006-12-01
MY157375A (en) 2016-06-15
UA82901C2 (en) 2008-05-26
KR20060061388A (ko) 2006-06-07
BRPI0415010A (pt) 2006-11-07
AU2004285855B2 (en) 2010-12-23
CA2542140C (en) 2012-05-29

Similar Documents

Publication Publication Date Title
EP4025572B1 (en) Heterocyclic rip1 kinase inhibitors
JP7034941B2 (ja) Lsd1/hdac二重阻害剤としてのシクロプロピル-アミド化合物
EP3510025B1 (en) Heteroaryl inhibitors of pad4
JP4959336B2 (ja) {2−[1−(3,5−ビストリフルオロメチルベンジル)−5−ピリジン−4−イル−1h−[1,2,3]トリアゾル−4−イル]−ピリジン−3−イル}−(2−クロロフェニル)−メタノンの新規の結晶形態
CN105829302B (zh) 用于ezh2抑制的盐酸盐形式
JP6254075B2 (ja) カリウムチャネル遮断剤としてのアミン誘導体
JP6619503B2 (ja) Cgrp受容体アンタゴニスト
JP2011509934A (ja) 結晶性(r)−2−(4−シクロプロパンスルフォニル−フェニル)−n−ピラジン−2−イル−3−(テトラヒドロピラン−4−イル)−プロピオンアミド
JP2011525924A (ja) プロリルヒドロキシラーゼ阻害剤
US20240317746A1 (en) Crystalline forms of an azetidine parp1 inhibitor
TWI802654B (zh) 一種酮基吡啶醯胺類衍生物的晶型及其製備方法
CN114591312B (zh) 一类砜及亚砜类化合物、其制备方法及医药用途
EP3481801B1 (en) Indoline derivatives and method for using and producing the same
EP1675846B1 (en) Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h- [1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
CN113840605B (zh) N-(5-((4-乙基哌嗪-1-基)甲基)吡啶-2-基)-5-氟-4-(3-异丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺盐酸盐的结晶形式及其用途
MXPA06004444A (en) Novel crystalline forms of {2-[1-(3, 5-bis-trifluoromethylbenzyl) -5-pyridin-4-yl -1h-[1, 2, 3]triazol -4-yl]- pyridin-3-yl}- (2-chlorophenyl) -methanone
JP2025503063A (ja) 硫黄含有イソインドリン系誘導体の結晶
JP3031634B2 (ja) D1アンタゴニスト/d2アンタゴニスト及び5ht2−セロトニンアンタゴニストとしてのピペリジニル置換メタノアントラセン
EA052388B1 (ru) Кристаллическая форма серосодержащего производного изоиндолина
BR102018073582B1 (pt) Enantiômero, processo de preparação de um enantiômero, uso do enantiômero, composição farmacêutica e combinação
HK40025351A (en) Crystal form of oxopicolinamide derivative and preparation method therefor
TW201514162A (zh) 作爲鉀離子通道抑制劑之呔

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM BY KZ KG MD TM